Clinical Trials Logo

HIV-facial Lipoatrophy clinical trials

View clinical trials related to HIV-facial Lipoatrophy.

Filter by:
  • None
  • Page 1

NCT ID: NCT02342223 Active, not recruiting - Clinical trials for HIV Facial Lipoatrophy

Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy

Start date: February 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of Voluma and see what effects it has on HIV facial lipoatrophy. The hypothesis is that Voluma will be safe, efficacious and positively impact the quality-of-life in the treatment of facial lipoatrophy in patients with HIV.

NCT ID: NCT02009462 Completed - Clinical trials for HIV-facial Lipoatrophy

Artefill for the Treatment of HIV-associated Facial Lipoatrophy

Start date: December 2013
Phase: Phase 1
Study type: Interventional

Artefill is an injectable facial filler device that is currently approved by the FDA for the correction of nasolabial folds. This study seeks to examine the use of Artefill in the treatment of HIV associated facial lipoatrophy. Facial lipoatrophy (facial fat loss) related to HIV is a stigmatizing condition characterized by loss of facial fat, most notably in the cheeks and temples.